EP3307304B1 - Immunglobulin-fusionsproteine und verwendungen davon - Google Patents

Immunglobulin-fusionsproteine und verwendungen davon Download PDF

Info

Publication number
EP3307304B1
EP3307304B1 EP16808386.3A EP16808386A EP3307304B1 EP 3307304 B1 EP3307304 B1 EP 3307304B1 EP 16808386 A EP16808386 A EP 16808386A EP 3307304 B1 EP3307304 B1 EP 3307304B1
Authority
EP
European Patent Office
Prior art keywords
sfc
fusion protein
seq
ifnα
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16808386.3A
Other languages
English (en)
French (fr)
Other versions
EP3307304A1 (de
EP3307304A4 (de
Inventor
Chang-Yi Wang
Wen-Jiun Peng
Wei-Ting Kao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UBI PHARMA Inc
Original Assignee
Ubi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/002,396 external-priority patent/US20160362473A1/en
Priority claimed from US15/177,605 external-priority patent/US11820807B2/en
Application filed by Ubi Pharma Inc filed Critical Ubi Pharma Inc
Publication of EP3307304A1 publication Critical patent/EP3307304A1/de
Publication of EP3307304A4 publication Critical patent/EP3307304A4/de
Application granted granted Critical
Publication of EP3307304B1 publication Critical patent/EP3307304B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to a therapeutic fusion protein comprising an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc fragment is a single chain.
  • An immunoglobulin comprises four polypeptide chains, two heavy chains and two light chains, that associate via interchain disulfide bonds.
  • Each light chain has two domains, a variable light domain (V L ) and a constant light domain (C L ); and each heavy chain has two regions, a variable heavy region (V H ) and a constant heavy region (C H ).
  • the constant heavy region (C H ) is composed of constant heavy domains that are designated by number (e.g., C H 1, C H 2, C H 3, etc.) (see e.g., US 6,086,875 (Blumberg R. S. et al. ); US 5,624,821 (Winter G. P. et al. ); and US 5,116,964 (Capon D. J.
  • Immunoglobulins are categorized into different isotypes based on their biological properties, location in an organism, and ability to deal with different antigens (i.e., IgG, IgM, IgA, IgD and IgE).
  • the constant heavy region Depending on the immunoglobulin isotype, the constant heavy region (C H ) can have three or four C H domains.
  • the heavy chains contain a hinge region that adds flexibility to the molecule ( Janeway et al. 2001, Immunobiology, Garland Publishing, N.Y., N.Y .).
  • IgG1 There are four IgG subclasses (IgG1, 2, 3, and 4) in humans, named in order of their abundance in serum (IgG1 being the most abundant).
  • the IgG isotype is composed of two light chains and two heavy chains, where each heavy chain contains three constant heavy domains (C H 1, C H 2, C H 3).
  • the two heavy chains of IgG are linked to each other and to a light chain each by disulfide bonds (-S-S-).
  • the antigen binding site of IgG is located in the Fragment antigen binding region (Fab region), which contains variable light (V L ) and variable heavy (V H ) chain domains as well as constant light (C L ) and constant heavy (C H 1) chain domains.
  • Fab region Fragment antigen binding region
  • the fragment crystallizable region (Fc region) of IgG is a portion of the heavy chain containing the C H 2 and C H 3 domains that binds to an Fc receptor found on the surface of certain cells, including the neonatal Fc receptor (FcRn).
  • the heavy chain of IgG also has a hinge region (hinge) between the C H 1 and C H 2 domains that separates the Fab region from the Fc region and participates in linking the two heavy chains together via disulfide bonds.
  • the structure of the hinge region contributes to unique biological properties of each of the four IgG subclasses.
  • IgG is secreted as a monomer that is small in size allowing it to easily perfuse tissues. It is the only isotype that has receptors (neonatal Fc receptor (FcRn)) that facilitate passage through the human placenta to provide protection to the fetus in utero. IgG absorbed through the placenta provides the neonate with humoral immunity before its own immune system develops.
  • FcRn nonatal Fc receptor
  • the IgG neonatal Fc receptor (FcRn) binding site is located in the Fc region of the antibody.
  • FcRn is normally expressed in human placenta and epithelial cells and participates in an endocytic salvage pathway that prevents degradation of IgG. This salvage pathway is mediated by the highly pH-dependent binding affinity of IgG to FcRn in acidic pH.
  • the high affinity of IgG for FcRn at acidic pH is believed to result in binding of internalized IgG to FcRn after uptake into acidic endosomes (Goebl NA, et al, 2008; Junghans RP, et al, 1996).
  • This salvage pathway provides one mechanism for developing next-generation protein drugs that have a prolonged half-life in blood circulation compared to unmodified protein drugs.
  • unmodified protein drugs have a short circulating half-life, making frequent dosing over an extended treatment period necessary.
  • Extensive efforts have been made to extend the half-life of the protein drugs by many means including PEGylation fusion protein technologies (U.S. Food and Drug Administration; Osborn BL, et al, 2002); however, the results from these efforts have not been ideal.
  • fusion proteins comprising IgG constant regions linked to a protein of interest, or fragment thereof, has been described.
  • protein "X" of interest is linked to an IgG "Fc" domain to create an "Fc-X” or "X-Fc” fusion protein (immunofusion).
  • Immunofusion proteins can generally be prepared and purified in larger quantities compared to other types of fusion proteins because the Fc moiety of the fusion protein is designed for efficient secretion by the cell.
  • Fusion proteins containing a Fc region of an immunoglobulin have been shown to have enhanced features compared to their non-Fc-containing counterparts, including increased protein stability and longer serum half-life ( see Capon et al.
  • FcRn neonatal Fc receptor
  • US 6,086,875 Blumberg R. S. et al.
  • US 6,485,726 Blumberg R. S. et al.
  • US 6,030,613 WO 03/077834
  • US 2003-0235536A1 Blumberg R. S. et al.
  • US 5,116,964 discloses a ligand binding partner protein which comprises a lymphocyte cell surface glycoprotein (LHR) and an immunoglobulin chain, in which the ligand binding partner protein and immunoglobulin are fused through either N-terminus amino or C-terminus carboxyl group.
  • LHR lymphocyte cell surface glycoprotein
  • WO 94/04689 discloses the use of Fc of immunoglobulin to provide a toxin with extended half-life that includes a ligand binding domain (CD4 receptor) and a Pseudomonas exotoxin A.
  • the IgG Fc links the CD4 receptor and a Pseudomonas exotoxin A.
  • hG-CSF-L-vFc fusion protein comprising human granulocyte colony-stimulating factor (hG-CSF), a flexible peptide linker (L) of about 20 or fewer amino acids, and a human IgG Fc variant.
  • the Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects.
  • Fc-IFN- ⁇ sol discloses a method and composition for expressing soluble, biologically active Fc-IFN- ⁇ fusion proteins and variants thereof (Fc-IFN- ⁇ sol ).
  • the Fc-IFN- ⁇ fusion protein includes an IFN- ⁇ protein linked to the carboxy-terminus of the immunoglobulin Fc region
  • fusion proteins having a two chain Fc fusion protein design with two bioactive molecules in close proximity to one another.
  • the bioactive molecules of these traditional fusion proteins are generally suppressed or sterically hindered from interacting with the target molecules or cells. Therefore, there is a need to develop a fusion protein comprising a bioactive molecule linked to a modified Fc region of an IgG, that can confer increased in vivo half-life of the bioactive molecules without suppressing the bioactivity of the bioactive molecule.
  • modified fusion proteins would provide an added benefit for ease of purification by related affinity purification processes.
  • the present disclosure is directed to novel fusion proteins comprising a portion of an immunoglobulin (Ig) molecule, compositions thereof, and methods for making the disclosed fusion proteins.
  • the disclosed fusion proteins are useful for extending the serum half-life of bioactive molecules in an organism.
  • the fusion protein of the present disclosure generally comprises (a) bioactive molecule selected from the group consisting of erythropoietin, Factor IX, IFN ⁇ , GCSF, and IFN ⁇ and (b) a single chain Fc (sFc) fragment of an IgG molecule having an amino acid sequence selected from the group consisting of SEQ ID NOs: 61, 62, 63, and 64, and c) a hinge region between the bioactive molecule and the sFc fragment, wherein the hinge region is mutated and does not form disulfide bonds with another fusion protein or another immunoglobulin molecule, and wherein the hinge region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 23-60.
  • amino acid sequence of the (a) bioactive molecule and (b) Ig fragment of the fusion protein are derived from the wild-type sequence of each fragment, as disclosed in the art. Derived sequences include the wild-type sequence as well as homologues, analogues, fragments, and other variants of the wild-type sequence.
  • the Ig fragment of the fusion protein comprises a single chain Fc (sFc or scFc), a monomer, that is incapable of forming a disulfide-bonded dimer.
  • the fusion protein further includes a sequence corresponding to an immunoglobulin hinge region.
  • the hinge region contains a modification that prevents the fusion protein from forming a disulfide bond with another fusion protein or another immunoglobulin molecule.
  • the hinge region is modified by mutating and/or deleting one or more cysteine amino acids to prevent the formation of a disulfide bond.
  • the bioactive molecule is linked to the scFc through a hinge region.
  • the fusion protein comprises the bioactive molecule at its N-terminus that is linked to a scFc through a mutated hinge region.
  • the present invention relates to compositions, including pharmaceutical compositions, comprising the fusion protein and a pharmaceutically acceptable carrier or excipient.
  • the method for making the fusion protein is carried out in a mammalian cell and comprises (i) providing a bioactive molecule and an sFc fragment comprising a hinge region, wherein the bioactive molecule selected from the group consisting of erythropoietin, Factor IX, IFN ⁇ , GCSF, and IFN ⁇ , (ii) mutating the hinge region of the sFc fragment by amino acid substitution and/or deletion to form a mutated hinge region of a mutated sFc fragment, and (iii) linking the bioactive molecule to the Fc fragment through the mutated hinge region to form the fusion protein, or composition thereof, wherein the mutated hinge region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 23-60, and wherein the mutated hinge region does not form disulfide bonds with another fusion protein or another immunoglobulin molecule.
  • the present disclosure is directed to novel fusion proteins comprising a bioactive molecule and portions of an immunoglobulin molecule.
  • Various aspects of the present disclosure relate to fusion proteins, compositions thereof, and methods for making and using the disclosed fusion proteins.
  • the disclosed fusion proteins are useful for extending the serum half-life of bioactive molecules in an organism.
  • fusion protein or a “fusion polypeptide” is a hybrid protein or polypeptide comprising at least two proteins or peptides linked together in a manner not normally found in nature.
  • One aspect of the present disclosure is directed to a fusion protein comprising an immunoglobulin (Ig) Fc fragment and a bioactive molecule as defined above.
  • the bioactive molecule that is incorporated into the disclosed fusion protein has improved biological properties compared to the same bioactive molecule that is either not-fused or incorporated into a fusion protein described in the prior art (e.g., fusion proteins containing a two chain Fc region).
  • the bioactive molecule incorporated into the disclosed fusion protein has a longer serum half-life compared to its non-fused counterpart.
  • the disclosed fusion protein maintains full biological activity of the bioactive molecule without any functional decrease, which is an improvement over the fusion proteins of the prior art that have a decrease in activity due to steric hindrance from a two chain Fc region.
  • fusion proteins of the present disclosure provide significant biological advantages to bioactive molecules compared to non-fused bioactive molecules and bioactive molecules incorporated into fusion proteins described in the prior art.
  • the disclosed fusion protein can have any of the following formulae (also shown in Figures 1A to 1D ): (B)-(Hinge)-(C H 2-C H 3) (Formula 1) ( Fig. 1A ) (C H 3-C H 2)-(Hinge)-(B) (Formula 2) ( Fig. 1B ) (B)-(L) m -(Hinge)-(C H 2-C H 3); or (Formula 3) ( Fig. 1C ) (C H 3-C H 2)-(Hinge)-(L) m -(B) (Formula 4) ( Fig. 1D ) wherein
  • the fusion protein of the present disclosure contains an Fc fragment from an immunoglobulin (Ig) molecule, selected from the group consisting of SEQ ID NOs: 61, 62, 63, and 64.
  • Ig immunoglobulin
  • Fc region refers to a portion of an immunoglobulin located in the c-terminus of the heavy chain constant region.
  • the Fc region is the portion of the immunoglobulin that interacts with a cell surface receptor (an Fc receptor) and other proteins of the complement system to assist in activating the immune system.
  • an Fc receptor cell surface receptor
  • the Fc region contains two heavy chain domains (C H 2 and C H 3 domains).
  • the Fc region contains three heavy chain constant domains (C H 2 to C H 4 domains).
  • the human IgG heavy chain Fc portion is usually defined to comprise residues C226 or P230 to its carboxyl-terminus, wherein the numbering is according to the EU index.
  • the fusion protein comprises a C H 2-C H 3 domain, which is an FcRn binding fragment, that can be recycled into circulation again. Fusion proteins having this domain demonstrate an increase in the in vivo half-life of the fusion proteins.
  • Fc fragment refers to the portion of the fusion protein that corresponds to an Fc region of an immunoglobulin molecule from any isotype.
  • the Fc fragment comprises the Fc region of IgG
  • the Fc fragment is a single chain Fc (sFc) fragment of an IgG molecule having an amino acid sequence selected from the group consisting of SEQ ID NOs: 61, 62, 63, and 64
  • the Fc fragment can be obtained or produced by any method known in the art.
  • the Fc fragment can be isolated and purified from an animal, recombinantly expressed, or synthetically produced.
  • the Fc fragment is encoded in a nucleic acid molecule (e.g., DNA or RNA) and isolated from a cell, germ line, cDNA library, or phage library.
  • the Fc region and/or Fc fragment includes a hinge region found in some immunoglobulin isotypes (IgA, IgD, and IgG).
  • the Fc fragment is modified by mutating the hinge region so that it does not contain any Cys and cannot form disulfide bonds.
  • the hinge region is discussed further below.
  • the Fc fragment of the disclosed fusion protein is a single chain Fc.
  • single chain Fc means that the Fc fragment is modified in such a manner that prevents it from forming a disulfide-bonded dimer (e.g., by chemical modification or mutation addition, deletion, or substation of an amino acid).
  • the Fc fragment of the fusion protein is derived from human IgG1, which can include the wild-type human IgG1 amino acid sequence or variations thereof.
  • the Fc fragment of the fusion protein contains an Asn amino acid that serves as an N-glycosylation site at amino acid position 297 of the native human IgG1 molecule (based on the European numbering system for IgG1, as discussed in U.S. Patent No. 7,501,494 ), which corresponds to residue 67 in the Fc fragment (SEQ ID NO: 61).
  • the N-glycosylation site in the Fc fragment is removed by mutating the Asn (N) residue with His (H) (SEQ ID NO: 62) or Ala (A) (SEQ ID NO: 63).
  • An Fc fragment containing a variable position at the N-glycosylation site is shown as SEQ ID NO: 64 in the Sequence Listing.
  • the C H 3-C H 2 domain of the Fc fragment has an amino acid sequence corresponding to the wild-type sequence (disclosed in SEQ ID NO: 61). In certain embodiments, the C H 3-C H 2 domain of the Fc fragment has the amino acid sequence of SEQ ID NO: 62, where the N-glycosylation site is removed by mutating the Asn (N) residue with His (H). In certain embodiments, the C H 3-C H 2 domain of the Fc fragment has the amino acid sequence of SEQ ID NO: 63, where the N-glycosylation site is removed by mutating the Asn (N) residue with Ala (A).
  • the disclosed fusion protein includes a hinge region found in some immunoglobulin isotypes (IgA, IgD, and IgG).
  • the hinge region separates the Fc region from the Fab region, and adds flexibility to the molecule, and can link two heavy chains via disulfide bonds. Formation of a dimer, comprising two C H 2-C H 3 domains, is required for the functions provided by intact Fc regions. Interchain disulfide bonds between cysteines in the wild-type hinge region help hold the two chains of the Fc molecules together to create a functional unit.
  • the hinge region is be derived from IgG, namely IgG1.
  • the hinge region can be a full-length or a modified (truncated) hinge region.
  • the hinge region contains a modification that prevents the fusion protein from forming a disulfide bond with another fusion protein or an immunoglobulin molecule.
  • the hinge region is modified by mutating and/or deleting one or more cysteine amino acids to prevent the formation of a disulfide bond.
  • the N-terminus or C-terminus of the full-length hinge region may be deleted to form a truncated hinge region.
  • the cysteine (Cys) in the hinge region can be substituted with a non-Cys amino acid or deleted.
  • the Cys of hinge region may be substituted with Ser, Gly, Ala, Thr, Leu, Ile, Met or Val.
  • Comparative Examples of wild-type and mutated hinge regions from IgG1 to IgG4 include the amino acid sequences shown in Table 1 (SEQ ID NOs: 1 to 22). Disulfide bonds cannot be formed between two hinge regions that contain mutated sequences of the inevntion.
  • the IgG1 hinge region of the invention was modified to accommodate various mutated hinge regions with sequences shown in Table 2 (SEQ ID NOs: 23-60).
  • the fusion protein may have the bioactive molecule linked to the N-terminus of the Fc fragment.
  • the fusion protein may have the bioactive molecule linked to the C-terminus of the Fc fragment.
  • the linkage is a covalent bond, and preferably a peptide bond.
  • one or more bioactive molecule may be directly linked to the C-terminus or N-terminus of the Fc fragment.
  • the bioactive molecule(s) can be directly linked to the hinge of the Fc fragment.
  • the fusion protein may optionally comprise at least one linker.
  • the bioactive molecule may not be directly linked to the Fc fragment.
  • the linker may intervene between the bioactive molecule and the Fc fragment.
  • the linker can be linked to the N-terminus of the Fc fragment or the C-terminus of the Fc fragment.
  • the linker includes amino acids.
  • the linker may includes 1-5 amino acids.
  • biologically active molecule refers to proteins, glycoproteins, and combinations thereof.
  • the bioactive molecule is selected from the group consisting of erythropoietin, Factor IX, IFN ⁇ , GCSF, and IFN ⁇ .
  • the biologically active molecule is erythropoietin (EPO).
  • EPO erythropoietin
  • Erythropoietin an acidic glycoprotein of approximately 34,000 dalton molecular weight, is a glycoprotein hormone involved in the maturation of erythroid progenitor cells into erythrocytes. It is essential in regulating levels of red blood cells in circulation.
  • Naturally occurring erythropoietin is produced by the liver during fetal life and by the kidney of adults and circulates in the blood and stimulates the production of red blood cells in bone marrow. See, Erythropoietin concentrated solution of European Pharmacopoeia.
  • the EPO protein has an amino acid sequence of SEQ ID NO: 65.
  • the biologically active molecule is Factor IX (FIX).
  • FIX Factor IX
  • FIX a globular protein which has a molecular weight of about 70,000 daltons, is a vitamin K-dependent protein which participates in blood coagulation. It is synthesized in the form of a zymogen and undergoes three types of post-translational modifications before being secreted into the blood. In man, the liver is the site of FIX synthesis. This protein participates in the blood coagulation cycle and is used for the treatment of hemophilia B patients. At the present time the only commercially available source of FIX is human plasma. See, Human coagulation Factor IX of European Pharmacopoeia.
  • the FIX protein has an amino acid sequence of SEQ ID NO: 67.
  • the biologically active molecule is Interferon alpha (IFN ⁇ ) or Interferon beta (IFN ⁇ ).
  • Interferons are glycoproteins (19-20 KDa), possessing anti-viral, immunomodulatory and anti-proliferative effects and are divided in to three classes (Types I, II and III) according to their structural homology and the specific receptor they associate with.
  • the type I IFN family includes numerous IFN alpha variants, a single IFN beta member, and lesser known IFN epsilon, kappa, omega and delta. However, all type I IFNs bind exclusively to the IFN alpha receptor (IFNAR).
  • IFN alphas are produced by leukocytes in response to different stimuli whereas IFN beta is produced by most cell types except leukocytes.
  • IFN beta has 30% amino-acid homology with IFN alpha but with higher binding affinity to IFNAR when compared to IFN alpha.
  • IFN alpha and beta are used in the treatment of various human cancers and disease of viral origin.
  • the IFN ⁇ protein is IFN ⁇ 8 having an amino acid sequence of SEQ ID NO: 69.
  • the IFN ⁇ protein has an amino acid sequence of SEQ ID NO: 73.
  • the biologically active molecule is granulocyte colony stimulating factor (GCSF).
  • Granulocyte colony stimulating factor (GCSF) is a 20 KDa glycoprotein with a 174- or 177-amino acids single polypeptide chain. The shorter form possesses greater activity and stability than the longer isoform and is the basis for commercial pharmaceutical GCSF products.
  • GCSF stimulates the proliferation of neutropenic progenitor cells and their differentiation into granulocytes, and also activates mature neutrophils. GCSF is most frequently used in the treatment of chemotherapy-induced neutropenia.
  • the GCSF protein has an amino acid sequence of SEQ ID NO: 71.
  • compositions including pharmaceutical compositions, comprising the fusion protein and a pharmaceutically acceptable carrier or excipient.
  • compositions can be prepared by mixing the fusion protein with optional pharmaceutically acceptable carriers.
  • Pharmaceutically acceptable carriers include solvents, dispersion media, isotonic agents and the like. Examples of carriers include water, saline solutions or other buffers (such as phosphate, citrate buffers), oil, alcohol, proteins (such as serum albumin, gelatin), carbohydrates (such as monosaccharides, disaccharides, and other carbohydrates including glucose, sucrose, trehalose, mannose, mannitol, sorbitol or dextrins), gel, lipids, liposomes, stabilizers, preservatives, antioxidants including ascorbic acid and methionine, chelating agents such as EDTA; salt forming counter-ions such as sodium; non-ionic surfactants such as TWEEN TM , PLURONICS TM or polyethylene glycol (PEG), or combinations thereof.
  • the pharmaceutical compositions can contain more than one active compound.
  • the formulation can contain one or more fusion protein and/or one or more additional beneficial compound(s).
  • the active ingredients can be combined with the carrier in any convenient and practical manner, e.g., by admixture, solution, suspension, emulsification, encapsulation, absorption and the like, and can be made in formulations such as powder (including lyophilized powder), suspensions that are suitable for injections, infusion, or the like. Sustained-release preparations can also be prepared.
  • the pharmaceutical compositions contains the fusion protein for human use.
  • the pharmaceutical compositions can be prepared in an appropriate buffer including, but not limited to, citrate, phosphate, Tris, BIS-Tris, etc. at an appropriate pH and can also contain excipients such as sugars (50 mM to 500 mM of sucrose, trehalose, mannitol, or mixtures thereof), surfactants (e.g., 0.025% - 0.5% of Tween 20 or Tween 80), and/or other reagents.
  • the formulation can be prepared to contain various amounts of fusion protein. In general, formulations for administration to a subject contain between about 0.1 mg/mL to about 200 mg/mL.
  • the formulations can contain between about 0.5 mg/mL to about 50 mg/mL; between about 1.0 mg/mL to about 50 mg/mL; between about 1 mg/mL to about 25 mg/mL; or between about 10 mg/mL to about 25 mg/mL of fusion protein. In specific embodiments, the formulations contain about 1.0 mg/mL, about 5.0 mg/mL, about 10.0 mg/mL, or about 25.0 mg/mL of fusion protein.
  • Another aspect of the present invention relates to methods for making a fusion protein and compositions thereof.
  • the method for making the fusion protein comprises (i) providing a bioactive molecule and an sFc fragment comprising a hinge region, (ii) modifying the hinge region to prevent it from forming a disulfide bond, and (iii) linking the bioactive molecule directly or indirectly to the scFc through the mutated hinge region to form the fusion protein, hybrid, conjugate, or composition thereof.
  • the present disclosure also describes a method for purifying the fusion protein, comprising (i) providing a fusion protein, and (ii) purifying the fusion protein by Protein A or Protein G-based chromatography media.
  • the fusion protein may alternatively be expressed by well known molecular biology techniques. Any standard manual on molecular cloning technology provides detailed protocols to produce the fusion protein of the invention by expression of recombinant DNA and RNA.
  • Any standard manual on molecular cloning technology provides detailed protocols to produce the fusion protein of the invention by expression of recombinant DNA and RNA.
  • To construct a gene expressing a fusion protein of this invention the amino acid sequence is reverse translated into a nucleic acid sequence, preferably using optimized codons for the organism in which the gene will be expressed.
  • a gene encoding the peptide or protein is made, typically by synthesizing overlapping oligonucleotides which encode the fusion protein and necessary regulatory elements.
  • the synthetic gene is assembled and inserted into the desired expression vector.
  • the synthetic nucleic acid sequences encompassed by this invention include those which encode the fusion protein of the invention, and nucleic acid constructs characterized by changes in the non-coding sequences that do not alter the biological activity of the molecule encoded thereby.
  • the synthetic gene is inserted into a suitable cloning vector and recombinants are obtained and characterized.
  • the fusion protein is expressed under conditions appropriate for the selected expression system and host.
  • the fusion protein is purified by an affinity column of Protein A or Protein G (e.g., SoftMax ® , AcroSep ® , Sera-Mag ® , or Sepharose ® ).
  • the fusion protein of the present invention can be produced in mammalian cells.
  • mammalian cells include monkey COS cells, CHO cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.
  • the invention also describes a method for producing a single chain Fc (sFc) region of an immunoglobulin G, comprising mutating, substituting, or deleting the Cys in a hinge region of Fc of IgG
  • the Cys is substituted with Ser, Gly, The, Ala, Val, Leu, Ile, or Met.
  • the Cys is deleted.
  • a fragment of the hinge is deleted.
  • the invention provides a method for producing a fusion protein in a mammalian cell comprising: (a) providing a bioactive molecule and an IgG sFc fragment comprising a hinge region, wherein the bioactive molecule selected from the group consisting of erythropoietin, Factor IX, IFN ⁇ , GCSF, and IFN ⁇ (b) mutating the hinge region of the sFc fragment by amino acid substitution and/or deletion to form a mutated hinge region of a mutated Fc without disulfide bond formation, and (c) combining the bioactive molecule and the mutated sFc fragment through the mutated hinge region, wherein the mutated hinge region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 23-60, and wherein the fusion protein is a monomer that is incapable of forming a dimer.
  • the fusion protein of the invention can be administered intravenously, subcutaneously, intra-muscularly, or via any mucosal surface, e.g., orally, sublingually, buccally, sublingually, nasally, rectally, vaginally, or via pulmonary route.
  • the dose of the fusion protein of the invention will vary depending upon the subject and the particular mode of administration.
  • the dosage required will vary according to a number of factors known to those skilled in the art, including, but not limited to, the fusion protein, the species of the subject and, the size of the subject. Dosage may range from 0.1 to 100,000 ⁇ g/kg body weight.
  • the fusion protein can be administered in a single dose, in multiple doses throughout a 24-hour period, or by continuous infusion.
  • the fusion protein can be administered continuously or at specific schedule.
  • the effective doses may be extrapolated from dose-response curves obtained from animal models.
  • a fusion protein was prepared having a structure of formula 1 discussed above: (B)-(Hinge)-(C H 2-C H 3) wherein:
  • the EPO-sFc was produced using a DNA expression vector.
  • the DNA fragment of the erythropoietin single chain Fc fusion protein (EPO-sFc) was assembled using overlapping primers by the method of assembly polymerase chain reaction (PCR).
  • the assembled EPO-sFc fragment was then ligated into PacI and EcoRV sites of pZD vector (pcDNA3.1Neo, Invitrogen, Carlsbad, CA, cat. no.V790-20 with dhfr gene) to obtain pZD/EPO-sFc as shown in Figure 2 and then transformed into E. coli.
  • the expression vector construct contained the zeocin-resistance gene as a selection marker.
  • CHO dhfr- cells were trypsinized and resuspended at a concentration of 3 ⁇ 10 6 cells/mL in CP-T buffer (Cyto pluse Cat. CP-T).
  • 0.2 mL of cell suspension (6 ⁇ 10 5 cells) was transfected with 10 ⁇ g of plasmid pZD/EPO-sFc by electroporation (PA4000 PulseAgile ® electroporator, Cyto Pulse Sciences). After 48 hrs of growth in non-selective medium, the transfectants were incubated in the selective complete medium containing IMDM, 10% fetal bovine serum, Zeocin (Invitrogen Cat. 1486406) and 5 nM MTX (Sigma Cat. BCL5707V) to obtain high yield clone zE93.
  • the expression of the secreted fusion protein in the culture medium was detected and quantified by Q-ELISA (Quantikine ® IVD ® Epo EL
  • the original zE93 cells were cultivated in a 10-cm dish containing IMDM supplemented with 10% FBS, zeocin, and 0.1 ⁇ M MTX.
  • Cells were maintained in a 37°C humidified 95% air/5% CO 2 incubator (Model 3326, Forma scientific).
  • the medium was changed from IMDM to JRH serum-free medium supplemented with 5% FBS, zeocin, and 0.1 ⁇ M MTX.
  • the cells were detached from 10-cm dish by trypsinization and then transferred to spinner flasks containing 50 mL JRH serum-free medium supplemented with the same percentage of FBS.
  • the cells When confluency reach 90% in 3-5 days, the cells were subcultured into spinner flask containing JRH serum-free medium supplemented with a lower percentage of FBS. Cells were adapted into lower serum conditions by stepwise decreasing the FBS percentage from 10% to 0% in spinner flasks.
  • the concentration of EPO-sFc fusion protein in serum samples were quantified by Quantikine ® IVD ® Epo ELISA kit (R&D Systems Inc., CN: DEP00).
  • the serum dilution-fold was optimized and the plate layout for standards, controls, and specimens were determined before performing formal assays using the fusion protein.
  • Absorbance at wavelength 450 nm and 600 nm was acquired by SoftMax ® Pro 5 software.
  • the buffer was exchanged to DEAE FF equilibrium buffer. Thereafter, the EPO-sFc containing cell medium prepared from high yield cell line as described Example 2 was loaded to DEAE FF 1 mL Hitrap column with a loading ratio at about 5.92 mg for 1 mL resin. After acidic wash step, the main peak was eluted by 40 mM Tris buffer containing 130mM NaCl, pH 8.0. DEAE FF eluate was then analyzed by Q-ELISA (Quantikine ® IVD ® EPO ELISA kit). The overall recovery rate was 15.48% (Table 3).
  • Table 3 reports information pertaining to the EPO-sFc fusion protein purified with MabSelect SuRe TM and DEAE FF, respectively.
  • the table shows that MabSelect SuRe TM yields high purity EPO-sFc efficiently by a single purification step.
  • FIG. 4 shows the EPO-sFc fusion protein produced using the methods discussed above revealed a major band by the SDS-PAGE (Lanes 1, 2, and 3).
  • the MW of EPO-sFc was between 50-70 KDa with high content of glycosylation which was shown in a duplicated SDS-PAGE gel by Periodic Acid-Schiff (PAS) staining method.
  • PAS Periodic Acid-Schiff
  • Sialic acid was one of the important components for EPO-sFc to affect its half-life in body circulation.
  • the MW of EPO-sFc was between 50-70 KDa with high content of glycosylation.
  • EPO-sFc was purified by different chromatographies including MabSelect SuRe TM and DEAE FF, respectively.
  • MabSelect SuRe TM could yield high purity EPO-sFc efficiently by a single purification step.
  • the DEAE FF anion exchange resin would provide further polish in purification to remove low sialic acid isoforms of EPO-sFc which might affect the half-life of EPO-sFc.
  • mice were purchased from BioLASCO Taiwan Co., Ltd. All rats were quarantined and acclimatized for four days prior to the initiation of the pharmacokinetic (PK) studies.
  • the rats were divided into three testing groups, for the PK studies: (1) EPO-sFc purified by DEAE; (2) EPO-sFc purified by Protein A; and (3) original recombinant human EPO (EPREX ® ).
  • the rats of groups (1) and (2) were dosed at 16.8 ⁇ g/kg and the rats of group (3) were dosed at 3.5 ⁇ g/kg.
  • the proteins were dosed via subcutaneous (S.C.) administration.
  • the rats were grouped and labeled with fur dye.
  • EPO-sFc EPO-sFc
  • EPO-sFc-(Protein A resin) at 16.8 ⁇ g/mL
  • fresh sample diluent 0.25% bovine serum albumin (AppliChem, CN: A0850,0250)
  • All injections were administered to the rats via the site of dorsal neck for S.C. route.
  • Blood samples were collected at 0.5, 1, 2, 5, 8, 12, 24, 48, 72, 96, 120, and 144 hours after injection and then centrifuged at 3,000 rpm for 20 minutes. The supernatant was stored at -70°C.
  • the EPO concentrations in serum samples were quantified by Quantikine ® IVD ® EPO ELISA kit (R&D Systems Inc., CN: DEP00). Before performing the assay, the serum dilution-fold was optimized and the plate was laid out for standards, controls, and specimens. The absorbances at wavelength 450 nm and 600 nm were acquired by SoftMax ® Pro 5 software. The Cmax, Tmax, AUC values, and the elimination phase half-life (T 1/2 ) from the EPO concentrations in serum were calculated by PK Solutions 2.0 TM software.
  • EPO-sFc The subcutaneous (S.C.) pharmacokinetic profiles of EPO-sFc purified from DEAE FF and EPREX ® in rats after administration with single dose are shown in Figure 6 and the mean pharmacokinetic features are shown in Table 5.
  • the half-life of EPO-sFc-DEAE was 22.3 ⁇ 0.38 (hrs). In contrast, the half-life of EPREX ® was only 6.182 ⁇ 0.675 (hrs).
  • the AUCs of EPO-sFc (DEAE) and EPREX ® were 327.4 ⁇ 15.13 and 161.5 ⁇ 23.64 (ng-hr/mL), respectively.
  • the Tmax of EPO-sFc (DEAE) and EPREX ® was 18 ⁇ 0.00 and 9.33 ⁇ 2.31 (hr), respectively.
  • EPO-sFc chronic kidney disease
  • EPO-sFc EPO-sFc fusion protein of the present disclosure
  • Reference drug EPREX ® , Johnson and Johnson
  • the EPO-sFc fusion protein produced according to Example 3 was freshly prepared at the concentrations of 0.336 ng/mL (equivalent molar to 40 IU/mL of EPREX ® ).
  • Each mouse was subcutaneously administered with 0.5 ml of EPREX ® or EPO-sFc fusion protein on day 1, and then blood collection was performed on days 4 to 9, 11, and 13.
  • the number of reticulocytes is a good indicator of biological activity of erythropoietin as it represents recent production and allows for the determination of reticulocyte count and erythropoietin potency.
  • the number of reticulocytes was determined by FACS. 1.0 mL of PBS and 5.0 ⁇ L of whole blood were added to a polystyrene tube for unstained sample. 1.0 mL of Thiazole Orange (BD Retic-Count TM , cn:349204) and 5.0 ⁇ L of whole blood were added to a polystyrene tube for stained sample. Both tubes were incubated in the dark at room temperature for 30 min, and then analyzed within 3.5 hours after incubation.
  • the samples were gently mixed immediately prior to analysis.
  • the reticulocytes was determined by flow-cytometry (BD FACSCalibur TM ) and analyzed by CellQuest Pro TM software.
  • the percentage of reticulocytes of each sample was calculated to evaluate the efficacy area under the curve (AUC) and maximal percentage of reticulocyte (RET max ) by PK solutions 2.0 software (Summit, Montrose, CO, USA).
  • the reticulocyte counts were used to compare the activity of reference drug and EPO-sFc fusion protein by measuring AUEC and RET max (Table 7).
  • the AUEC of 0 to 13 hours was 88.69 and 91.03 ng•hr/ml for EPREX ® and EPO-sFc fusion protein, respectively.
  • the RETmax of EPREX ® and EPO-sFc fusion protein was 11.12% and 10.48%, respectively.
  • the results of AUEC and RET max suggests that the single chain Fc portion of the EPO-sFc fusion protein does not significantly interfere with the function of the EPO portion since the biological activity of EPO-sFc was comparable to EPREX ® in this Example.
  • a fusion protein was prepared having a structure of formula 1 discussed above: (B)-(Hinge)-(C H 2-C H 3) wherein:
  • the FIX-sFc was produced using a DNA expression vector.
  • the DNA fragment of the Factor IX was assembled using overlapping primers by the method of assembly PCR.
  • the full-length gene of Factor IX single chain Fc fusion protein (FIX-sFc) was amplified from the reaction mixture, ligated into PacI and ApaI sites of pZD vector (pcDNA3.1Neo, Invitrogen, Carlsbad, CA, cat. no.V790-20 with dhfr gene) to obtain pZD/FIX-sFc as shown in Figure 3 and then transformed into E. coli.
  • the expression vector construct contained the zeocin-resistance gene as a selection marker.
  • CHO dhfr- cells were trypsinized and resuspended at a concentration of 3 ⁇ 10 6 cells/mL in CP-T buffer (Cyto pluse Cat. CP-T). Then 0.2 mL of the cell suspension (6 ⁇ 10 5 cells) was transfected with 15 ⁇ g of plasmid pZD/FIX-sFc by electroporation for the expression of rhFIX-sFc (PA4000 PulseAgile ® electroporator, Cyto Pulse Sciences). After 48 hrs of growth in non-selective medium, the transfectants were cultured under selective complete medium containing IMDM, 10% fetal bovine serum, Geneticin (Invitrogen Cat.
  • the capture antibody (mouse Factor IX monoclonal antibody, Bioporto, Denmark, Cat. HYB 133-09) in 1:1000 (1 ⁇ g/mL) was prepared in carbonate/bicarbonate coating buffer for use. 100 ⁇ l of the diluted capture antibody was added into wells of ELISA plate and incubated at 4°C overnight.
  • a detection antibody (Rabbit factor IX polyclonal Ab, Abcam, (U.K.), Cat. Ab23335) was diluted in PBST (PBS with 0.05% Tween 20) at 1:1,000 and added to ELISA plates.
  • the original N18 clone was cultivated in a 10-cm dish containing IMDM supplemented with 5% FBS, zeocin, and 0.01 ⁇ M MTX.
  • Cells were maintained in a 37°C humidified 95% air/8% CO 2 incubator (Model 3326, Forma scientific).
  • the culture medium was changed from IMDM to EX-CELL ® 325 PF CHO Serum-Free Medium supplemented with 2% FBS, zeocin, and 0.02 ⁇ M MTX.
  • Cells from the high yield clone, N18-reZB were subsequently sorted by FACS to separate therein the high yield cell group and grow under EX-CELL ® 325 PF CHO Serum-Free Medium. Cells from the clone N18-reZB were tested by different MTX condition to select cells producing high yield of rhFIX-sFc.
  • N18-reZB-sp4-sp5 was further selected by Q-ELISA MTX challenge. Subsequently, the serum-free clone was retransfected with pZD/FIX-sFc by sorting and MTX challenging and subjected to function selection leading to high-yield clones. N18-reZB-sp4-sp5 was obtained in this process. The accumulated titer in batch culture of N18-reZB-sp4-sp5 was about 53.4 ⁇ g/mL as determined by the Q-ELISA.
  • FIX-sFc producing cell line culture medium was applied to a Protein A based MabSelect SuRe TM column with a loading ratio about 1.84 mg for 1 mL resin. After 2 washing steps, the fusion protein was eluted from the column by pH 3.0 buffer. MabSelect SuRe TM eluate was analyzed by Q-ELISA to determine the quantity and recovery rate. The FIX-sFc was captured by MabSelect SuRe TM efficiently and a single step purification already yielded a highly purified preparation as shown in Lane 2 of Figure 5 .
  • the IXSelect affinity (GE; no.: 17-5505-01) resin was packed in 1 mL column.
  • the resin was coupled with monoclonal antibody directed against FIX.
  • the range of loading pH was from 6.5-8.0.
  • the FIX-sFc medium was loaded to IXSelect column without buffer exchange.
  • the loading ratio was about 1.69 mg for 1 mL resin.
  • the main peak was eluted by 20 mM Tris containing 2 M MgCl 2 , pH 7.4 buffer. Thereafter, IXSelect eluate was analyzed by Q-ELISA.
  • Table 4 reports information pertaining to the FIX-sFc fusion protein purified with MabSelect SuRe TM and IX Select affinity resin, respectively.
  • the table shows that MabSelect SuRe TM and IX Select yield high purity FIX-sFc efficiently by a single purification step.
  • Figure 5 shows the FIX-sFc fusion protein produced using the methods discussed above revealed a major band by the SDS-PAGE (Lanes 1 and 2).
  • the MW of Factor IX-sFc was between 100-110 KDa with high content of glycosylation which was shown in a duplicated SDS-PAGE gel by Periodic Acid-Schiff (PAS) staining method.
  • the recovery rate of MabSelect SuRe TM and IXSelect was 88.34% and 20.05%, respectively (Table 4).
  • FIX-sFc pharmacokinetic studies: (1) recombinant FIX (BeneFIX ® ) as a reference drug; and (2) FIX-sFc of the present disclosure.
  • the rats of group (1) and (2) were dosed at 1 mg/kg via tail vein on Day 0. After injection, the rats were bled at 0, 0.25, 4, 8, 24, 48, 72, 96 and 168 hours after injection according to the testing schedule.
  • the coagulant free blood samples were placed at room temperature for at least 30 minutes with the serum isolated by centrifugation at 3,000 rpm for 20 minutes. The serum samples were aliquoted and stored at -70°C until analysis.
  • the diluted capture antibody (mouse Factor IX monoclonal antibody, Bioporto, Denmark, Cat. HYB 133-09) in 1:1000 (1 ⁇ g/mL) was prepared using carbonate/bicarbonate coating buffer.
  • a buffer capsule (Sigma, Cat. # C-3041) was dissolved in 100 mL ddH 2 O to yield 0.05 M buffer, pH 9.6, filtrated by 0.2 ⁇ m filter, and stored at 4 °C. 100 ⁇ l of the diluted captured antibody was added into wells of ELISA plate and incubated at 4 ° C overnight.
  • the plates were blocked using 200 ⁇ l of blocking buffer (PBS, pH 7.2 containing 2.0 % BSA), and washed 3 times with 200 ⁇ l of PBS (PBS, pH 7.2).
  • 100 ⁇ l of BeneFIX ® 100 ng/mL, 50 ng/mL, 25 ng/mL, 12.5 ng/mL, 6.25 ng/mL, 3.125ng/mL, and 1.5625 ng/mL
  • FIX-sFc 100 ⁇ l of BeneFIX ® (100 ng/mL, 50 ng/mL, 25 ng/mL, 12.5 ng/mL, 6.25 ng/mL, 3.125ng/mL, and 1.5625 ng/mL) and FIX-sFc at corresponding concentrations were added to each ELISA well, respectively, and incubated at 37 °C for 1 hour.
  • the ELISA plates were then washed 3 times with 200 ⁇ l of PBST (PBS with
  • a detection antibody (Rabbit factor IX polyclonal Ab, Abeam, (U.K.), Cat. Ab23335) was diluted in PBST (PBS with 0.05% Tween 20) by 1:1,000 and added into ELISA plates. After incubation, the ELISA plates were washed 3 times with PBST. HRP conjugate antibody (Peroxidase-AffiniPure Goat Anti-Rabbit Ab, Jackson ImmunoResearch, (USA), Cat.111-035-144) and TMB Peroxidase Substrate (KPL, Cat.53-00-03) were added into the plates to produce color. Finally, 100 ⁇ l 1 N H 2 SO 4 was used to stop the reaction.
  • the absorbances of diluted serum at wavelength 450 nm and 600 nm were acquired by SoftMax ® Pro 5 software.
  • the C initial value, AUC value and elimination phase half-life (T 1/2 ) were calculated by the concentration of FIX-sFc using PK solution 2.0 TM software.
  • the intravenous (I.V.) pharmacokinetic profiles of FIX-sFc purified from MabSelect SuRe TM and BeneFIX ® in rats after administration with a single dose are shown in Figure 7 and the mean pharmacokinetic features are shown in Table 6.
  • the half-life of FIX-sFc and BeneFIX ® were 56.0 ⁇ 13.1 and 11.91 ⁇ 2.54 (hrs), respectively.
  • the AUCs of FIX-sFc and BeneFIX ® were 19080.3 ⁇ 2606.4 and 46594.40 ⁇ 3634.08 (ng-hr/mL), respectively.
  • the C initial of FIX-sFc and BeneFIX ® were 4668.0 ⁇ 447.5 and 11790.98 ⁇ 4898.85 (ng/mL), respectively.
  • the half-life of FIX-sFc of the present invention was about 56 hours in rats with I.V administration, which is 5X longer than that (11.91 ⁇ 2.54 hrs) of BeneFIX ® .
  • the FIX-sFc is, therefore, a long-acting drug for hemophilia patients to decrease the injection frequency and improve patient's quality of life.
  • the pharmacokinetic data indicated that the FIX-sFc of the invention might be bound to the Fc receptor, resulting in a lower C initial concentration and AUC and released slowly back into the blood stream, resulting in its longer half-life.
  • Activated Partial Thromboplastin Time (APTT) test was used to determine the biological activity of FIX-sFc.
  • the samples (BeneFIX ® or FIX-sFc) were then mixed with equal volume of Dade ® Actin ® FSL Reagent (Siemens Healthcare Diagnostics Products GmbH) and incubated at 37°C for 3 min.
  • CaCl 2 was added to stop the clotting reaction and observe the clot formation. The clotting time and specific activity were recorded and calculated by parallel line method (PLA analysis).
  • the clotting time was dependent on the concentration of BeneFIX ® or FIX-sFc.
  • the average APTT result was 30.1, 26.2, and 25.5 sec for the FIX-sFc at the concentration of 2.5, 5.0, and 10.0 ⁇ g/ml, respectively.
  • the FIX-sFc had a similar relative potency and specific activity compared to BeneFIX ® .
  • FIX-sFc maintained an equivalent biological activity to BeneFIX ® , which suggests that the single chain Fc does not interfere with the function of FIX in the fusion protein.
  • IFN ⁇ interferon alpha
  • IFN ⁇ single chain fusion protein (IFN ⁇ -sFc) was prepared having a structure of formula 1 discussed above: (B)-(Hinge)-(C H 2-C H 3) wherein:
  • the full-length amino acid sequence of the IFN ⁇ -sFc fusion protein is shown in the Sequence Listing as SEQ ID NO: 70.
  • the IFN ⁇ -sFc was produced using a DNA expression vector.
  • the DNA fragment of IFN ⁇ -sFc was assembled using overlapping primers by the method of assembly polymerase chain reaction (PCR).
  • PCR assembly polymerase chain reaction
  • the assembled IFN ⁇ -sFc fragment was then ligated into PacI and EcoRV sites of pZD vector (pcDNA3.1Neo, Invitrogen, Carlsbad, CA, cat. no.V790-20 with dhfr gene) to obtain pZD/IFN ⁇ -sFc as shown in Figure 8 and then transformed into E. coli.
  • the expression vector construct contained the zeocin-resistance gene as a selected marker.
  • CHO dhfr- cells were trypsinized and resuspended at a concentration of 3 ⁇ 10 6 cells/mL in CP-T buffer (Cyto pluse Cat. CP-T).
  • 0.2 mL of cell suspension (6 ⁇ 10 5 cells) was transfected with 10 ⁇ g of plasmid pZD/IFN ⁇ -sFc by electroporation (PA4000 PulseAgile ® electroporator, Cyto Pulse Sciences). After 48 hrs of growth in non-selective medium, the transfectants were incubated in the selective complete medium containing IMDM, 10% fetal bovine serum, Zeocin (Invitrogen Cat.
  • the original 22-123-327-117-Re117 cells were cultivated in a 10-cm dish containing IMDM supplemented with 10% FBS, zeocin, and 0.1 ⁇ M MTX.
  • Cells were maintained in a 37°C humidified 95% air/5% CO 2 incubator (Model 3326, Forma scientific).
  • the medium was changed from IMDM to JRH serum-free medium supplemented with 5% FBS, zeocin, and 0.1 ⁇ M MTX.
  • the cells were detached from 10-cm dish by trypsinization and then transferred to spinner flasks containing 50 mL JRH serum-free medium supplemented with the same percentage of FBS.
  • the cells When confluency reached 90% in 3-5 days, the cells were subcultured into spinner flask containing JRH serum-free medium supplemented with a lower percentage of FBS. Cells were adapted into lower serum conditions by stepwise decreasing the FBS percentage from 10% to 0% in spinner flasks.
  • the concentration of IFN ⁇ -sFc fusion protein in serum samples was quantified by an in-house IFN ⁇ -sFc ELISA kit. Absorbance at wavelength 450 nm and 600 nm was acquired by SoftMax ® Pro 5 software. High-yield clones were successfully obtained by selection, limiting dilution and stepwise MTX challenges to produce finally the fusion protein comprising the recombinant IFN alpha8 linked to single chain Fc (i.e., IFN ⁇ -sFc). The resulting fusion protein was purified for further in vitro or in vivo biological activity assays and pharmacokinetics studies.
  • Protein A based resin (MabSelect SuRe TM ) was used to purify IFN ⁇ -sFc. After purification, the corresponding recovery rate was analyzed by quantitative ELISA, and the respective purity by SDS-PAGE. The detailed purification processes for IFN ⁇ -sFc fusion protein is described below.
  • IFN ⁇ -sFc was purified by MabSelect SuRe TM using different buffer conditions. The results showed that the 0.1 M Glycine pH3.0 elution buffer could purify IFN ⁇ -sFc efficiently with high purity for further determination of the physical-chemical properties.
  • the eluates of purified IFN ⁇ -sFc samples were analyzed by SDS-PAGE as shown in Figure 9 which revealed the purified IFN ⁇ -sFc as a major band in all buffers evaluated.
  • the stabilizing additives sucrose or urea
  • the purity of IFN ⁇ -sFc in the glycine elution buffer having a sucrose additive was found to be > 95%.
  • mice Eight rats, weighing from 276-300g, were purchased from BioLASCO Taiwan Co., Ltd. All rats were quarantined and acclimatized for four days prior to the initiation of the pharmacokinetic (PK) studies. The rats were divided into four testing groups for the PK studies: (1) Pegasys ® (pegylated IFN ⁇ ), (2) IFN ⁇ -sFc of this disclosure, (3) Peg-Intron ® (pegylated IFN ⁇ ), and (4) Roferon-A ® (recombinant IFN ⁇ ).
  • Pegasys ® pegylated IFN ⁇
  • IFN ⁇ -sFc of this disclosure
  • Peg-Intron ® pegylated IFN ⁇
  • Roferon-A ® recombinant IFN ⁇
  • the rats were dosed at 310 pmol/kg, which was converted equivalently into 18.6 ⁇ g/kg for Pegasys ® , 13.95 ⁇ g/kg for IFN ⁇ -sFc, 9.7 ⁇ g/kg for Peg-Intron ® and 5.89 ⁇ g/kg for Roferon-A ® .
  • All articles were freshly prepared with fresh sample diluents, 0.2% bovine serum albumin (AppliChem, CN: A0850,0250) in phosphate-buffered saline.
  • the rats were grouped and labeled with fur dye. All injections were administered to the rats via the site of dorsal neck for subcutaneous (S.C.) route.
  • Blood samples were collected at 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 192, 240, 288 and 336 hours after injection respectively and then centrifuged at 3,000 rpm for 20 minutes. The supernatants were stored at -70°C. Additional blood samples were collected and stored for the rats dosed with Roferon-A ® at 0.08, 0.25, and 8 hours after injection.
  • the interferon concentration in serum samples was quantified by ELISA method. Before performing the assay, the serum dilution-fold was optimized and the plate was laid out for standards, controls, and specimens. The absorbances at wavelength 450 nm and 600 nm were acquired by SoftMax ® Pro 5 software. The Cmax, Tmax, and AUC values and the elimination phase half-life (T 1/2 ) from the IFN concentrations in serum were calculated by PK Solutions 2.0 TM software.
  • the subcutaneous (S.C.) pharmacokinetic profiles of the different treatment Groups after administration with single dose are shown in Figure 10 with their mean pharmacokinetic features shown in Table 9.
  • the half-life of Pegasys ® , IFN ⁇ -sFc, Peg-Intron ® and Roferon-A ® was 23.2, 50.2, 20.8 and 0.73 hrs, respectively.
  • the AUCs of Pegasys ® , IFN ⁇ -sFc, Peg-Intron ® and Roferon-A ® were 64694.5, 60621.9, 5307.6 and 489.2 pM/h, respectively.
  • the Tmax of Pegasys ® , IFN ⁇ -sFc, Peg-Intron ® , and Roferon-A ® were 32.0, 32.0, 6.0 and 0.67 hr, respectively.
  • Roferon-A ® is a first generation recombinant IFN ⁇ product.
  • Pegasys ® and Peg-Intron ® are both second generation products of IFN ⁇ , with PEG (polyethylene glycol) coupled to the native IFN ⁇ .
  • PEG polyethylene glycol
  • the inclusion of PEG has previously been shown to significantly prolong the half-life of IFN ⁇ compared to the non-pegylated form.
  • the increase in half-life by PEG was also observed in this Example, as shown by the pharmacokinetic data reported in Table 9 and Figure 10 (compare the data for Pegasys ® and Peg-Intron ® with the data for Roferon-A ® ).
  • Table 9 and Figure 10 also show that the half-life of IFN ⁇ is prolonged even further, compared to Pegasys ® , Peg-Intron ® , and Roferon-A ® , when it is present in a single chain Fc fusion protein of the present disclosure.
  • the half-life of IFN ⁇ -sFc is more than 2 times longer than the two PEGylated interferons (Pegasys ® and Peg-Intron ® ) and more than 68 times longer than recombinant IFN ⁇ (Roferon-A ® ).
  • Antiviral activity of the IFN was determined by a cytopathic effect (CPE) inhibition assay.
  • CPE cytopathic effect
  • the wells of 96-well plates were seeded with 1.0 ⁇ 10 4 A549 cells and incubated at 37°C in a 5% CO 2 incubator for 24 hours. When cell growth formed confluent monolayers, cells were treated with various concentrations and forms of IFN ⁇ . Five-fold serial dilutions of the IFNs were prepared starting at a concentration of 178 ng/mL. The final volume of IFN added to the wells was 100 ⁇ l.
  • a four-parameter logistic curve and a 50% viral replication inhibition dose were both calculated by Sigma Plot software.
  • IFN ⁇ -sFc sFc fragment incapable of forming disulfide-bonded dimer
  • IFN ⁇ -Fc sFc fragment capable of forming disulfide-bonded dimer
  • IFN ⁇ single chain Fc fusion protein of this disclosure has improved biological properties and advantages compared to other IFN ⁇ products, including: (1) reduction in production cost by increasing purification yield through Protein A chromatography, (2) enhancement in anti-viral activity, (3) longer serum half-life, resulting in a decrease in dosing frequency, and (4) reduction in renal clearance.
  • IFN ⁇ -Fc dimerized Fc fusion protein
  • Pegasys ® Pegasys ®
  • the lower biological activities seen with IFN ⁇ -Fc and Pegasys ® is likely caused, at least in part, by the steric interference of receptor binding with the larger fusion molecules (i.e., sFc fragment capable of forming a disulfide-bonded dimer in IFN ⁇ -Fc and the branched 40 kDa PEG chain in Pegasys ® ).
  • the larger fusion molecules i.e., sFc fragment capable of forming a disulfide-bonded dimer in IFN ⁇ -Fc and the branched 40 kDa PEG chain in Pegasys ® .
  • binding affinities of the interferon fusion proteins were determined by Kinetic/Affinity assay.
  • rhIFN alpha receptor 2 (IFNAR2) (Sino biotechnology, CN.: 10359-H08H) prepared in immobilization buffer (10 mM sodium acetate buffer, pH 4.0).
  • SPR Surface Plasmon Resonance
  • IFN ⁇ -sFc or IFN ⁇ -Fc Sample solutions containing 12.5 to 200 nM IFN ⁇ -sFc or IFN ⁇ -Fc were prepared by a 2-fold series dilution with running buffer (PBS with 0.005% Tween 20, pH 7.4). Solutions prepared in previous steps were diluted by 2-fold series with running buffer to prepare 6.25 to 100 nM IFN ⁇ -sFc or IFN ⁇ -Fc single injection solutions. Then, 200 nM IFN-alpha receptor 1 (IFNAR1) (Sino biotechnology, CN.: 13222-H08H) solution was mixed with equal volume of IFN single injection solution prepared in previous step to prepare IFN-IFNAR1 mixture.
  • IFNAR1 IFN-alpha receptor 1
  • the concentration of IFNAR1 was 100 nM, while the concentration of IFN ⁇ -sFc or IFN ⁇ -Fc ranged from 6.25 nM to 100 nM.
  • the equilibrium association constant (Ka) and equilibrium dissociation constant (Kd) values of IFN ⁇ -sFc or IFN ⁇ -Fc were analyzed by BIAevaluation software to calculate the binding constant (KD) values by the Kd and Ka.
  • IFN ⁇ -sFc--IFNAR1 and IFN ⁇ -Fc--IFNAR1 had similar binding profiles. Specifically, Table 11 shows that the binding associations of the IFNs were relatively similar, with IFN ⁇ -sFc having a Ka of 1.4E+06 1/Ms and IFN ⁇ -Fc having a Ka of 3.3E+06 1/Ms, respectively. However, in the dissociation stage, IFN ⁇ -sFcIFNAR1 had a slower dissociation profile (Kd) than that of IFN ⁇ -Fc--IFNAR1.
  • the dissociation (Kd) of IFN ⁇ -sFc and IFN ⁇ -Fc from IFNAR1 was 5.6E-03 and 5.6E-02 1/s, respectively.
  • the affinity of interaction (KD) of IFN ⁇ -sFc and IFN ⁇ -Fc to IFNAR was determined to be 4.0E-09 and 1.7E-08 nM, respectively, based on the association (Ka) and dissociation (Kd) profiles observed. Therefore, the affinity of IFN ⁇ -sFc was 4.25-fold higher than IFN ⁇ -Fc for forming the ternary complexes.
  • a fusion protein was prepared having a structure of formula 1 discussed above: (B)-(Hinge)-(C H 2-C H 3) wherein:
  • the GCSF-sFc was produced using a DNA expression vector.
  • the DNA fragment of the granulocyte-colony stimulating factor single chain Fc fusion protein (GCSF-sFc) was assembled using overlapping primers by the method of assembly polymerase chain reaction (PCR).
  • the assembled GCSF-sFc fragment was then ligated into PacI and EcoRV sites of pZD vector (pcDNA3.1Neo, Invitrogen, Carlsbad, CA, cat. no.V790-20 with dhfr gene) to obtain pZD-GCSF-sFc as shown in Figure 13 and then transformed into E. coli.
  • the expression vector construct contained the zeocin-resistance gene as a selection marker.
  • CHO dhfr- cells were trypsinized and resuspended at a concentration of 3 ⁇ 10 6 cells/mL in CP-T buffer (Cyto pluse Cat. CP-T).
  • 0.2 mL of cell suspension (6 ⁇ 10 5 cells) was transfected with 10 ⁇ g of plasmid pZD-GCSF-sFc by electroporation (PA4000 PulseAgile ® electroporator, Cyto Pulse Sciences). After 48 hrs of growth in non-selective medium, the transfectants were incubated in the selective complete medium containing IMDM, 10% fetal bovine serum, Zeocin (Invitrogen Cat. 1486406) and 5 nM MTX (Sigma Cat. BCL5707V) to obtain high yield clone zG3-17-41. The expression of the secreted fusion protein in the culture medium was detected and quantified by Q-ELISA.
  • the original zG3-17-41 cells were cultivated in a 10-cm dish containing IMDM supplemented with 10% FBS, zeocin, and 0.1 ⁇ M MTX.
  • Cells were maintained in a 37°C humidified 95% air/5% CO 2 incubator (Model 3326, Forma scientific).
  • the medium was changed from IMDM to JRH serum-free medium supplemented with 5% FBS, zeocin, and 0.1 ⁇ M MTX.
  • the cells were detached from 10-cm dish by trypsinization and then transferred to spinner flasks containing 50 mL JRH serum-free medium supplemented with the same percentage of FBS.
  • Cells were adapted into lower serum conditions by stepwise decreasing the FBS percentage from 10% to 0% in spinner flasks.
  • the concentration of GCSF-sFc fusion protein in serum samples was quantified by GCSF-sFc ELISA analysis. Absorbance at wavelength 450 nm and 600 nm was acquired by SoftMax ® Pro 5 software. High-yield clones were successfully obtained by selection, limiting dilution and stepwise MTX challenges to produce finally the fusion protein comprising the recombinant GCSF linked to single chain Fc (i.e., GCSF-sFc). The resulting fusion protein was purified for further in vitro or in vivo biological activity assays and pharmacokinetics studies.
  • Protein A based resin (MabSelect SuRe TM ) was used to purify GCSF-sFc. After purification, the corresponding recovery rate was analyzed by quantitative ELISA, and the respective purity by SDS-PAGE. The detailed purification process for GCSF-sFc is described below.
  • PK studies Nine rats, weighing from 180-200g, were purchased from BioLASCO Taiwan Co., Ltd. All rats were quarantined and acclimatized for four days prior to the initiation of the pharmacokinetic (PK) studies. The rats were divided into three testing groups for the PK studies: (1) GCSF-sFc, (2) Lenograstim (Granocyte ® ), a recombinant GCSF, and (3) Peg-filgrastim (Neulasta ® ), a PEGylated form of recombinant human GCSF.
  • the rats were dosed at 221.43 ⁇ g/Kg for GCSF-sFc and a molar equivalence of 100 ⁇ g/Kg for Lenograstim and Peg-filgrastim. All GCSF products were freshly prepared with sample diluents, 0.2% bovine serum albumin (AppliChem, CN: A0850,0250) in phosphate-buffered saline. The rats were grouped and labeled with fur dye. All injections were administered to the rats via the site of dorsal neck for subcutaneous (S.C.) route.
  • S.C. subcutaneous
  • Blood samples were collected at 5 min, 0.5, 1, 2, 3, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after injection respectively and then centrifuged at 3,000 rpm for 20 minutes. The supernatants were stored at -70°C.
  • the GCSF concentrations in serum samples were quantified by ELISA method using paired antibodies (R&D System, CN: MAB214 and R&D System, CN: BAF214) to bind and detect GCSF.
  • the serum dilution-fold was optimized and the plate was laid out for standards, controls, and specimens.
  • the absorbances at wavelength 450 nm and 600 nm were acquired by SoftMax ® Pro 5 software.
  • the Cmax, Tmax, and AUC values and the elimination phase half-life (T 1/2 ) from the GCSF concentrations in serum were calculated by PK Solutions 2.0 TM software.
  • the subcutaneous (S.C.) pharmacokinetic profiles of the respective GCSFs in rats after administration with single dose are shown in Figure 15 with their mean pharmacokinetic features shown in Table 12.
  • the half-life of GCSF-sFc, Lenograstim, and Peg-filgrastim was 17.16, 4.1 and 12.0 hrs, respectively.
  • the Cmax of GCSF-sFc, Lenograstim, and Peg-filgrastim was 906.9, 156.4 and 480.8 ng/mL, respectively.
  • the Tmax of GCSF-sFc, Lenograstim, and Peg-filgrastim was 48, 0.5 and 10.3 hrs, respectively.
  • the AUC of GCSF-sFc, Lenograstim, and Peg-filgrastim was 50624, 790-1292, and 23202 ⁇ 2921 ng-h/mL, respectively.
  • Lenograstim is a first generation recombinant GCSF product.
  • Peg-filgrastim is a second generation product of GCSF coupled to PEG (polyethylene glycol).
  • PEG polyethylene glycol
  • the inclusion of PEG has previously been shown to prolong the half-life of GCSF when compared to the first generation product (Lenograstim).
  • the increase in GCSF half-life with PEG was also observed in this Example, as shown in the pharmacokinetics data reported in Table 12 and Figure 15 (compare the data for Lenograstim with the data for Peg-filgrastim).
  • Table 12 and Figure 15 also show that the half-life of GCSF is prolonged even further, compared to Lenograstim and Peg-filgrastim, when GCSF is present in a single chain Fc fusion protein of the present disclosure. Specifically, the half-life of GCSF-sFc is nearly one and a half times longer than PEGylated GCSF (Peg-filgrastim) and more than 4 times longer than recombinant GCSF (Lenograstim).
  • mice were used to analyze GCSFs potency in comparison to the native GCSF, i.e. Lenograstim (Granocyte ® ).
  • Lenograstim Granocyte ®
  • 30 male BALB/cByJNarl mice aged 6 weeks were divided into six groups (i.e., five mice per group). All mice were treated with CPA (Cyclophosphamide monohydrate; Sigma, CN.: C7397) (100 mg/kg) on day 0.
  • Group A as the control group only received a 0.9% NaCl/0.1% BSA solution on day 1.
  • Three reference groups received Lenograstim (Chugai, CN.: N3L212) in a single shot (Groups B1 and B2) or four shots (Group B3) containing a dose of 51.02, 116.07 and 12.75 ⁇ M/kg, respectively.
  • Two test groups received a single shot of GCSF-sFc containing a dose of 51.02 ⁇ M/kg (Group C1) and 116.07 ⁇ M/kg (Group C2).
  • the groups that received a single shot (Groups A, B1, B2, C1, and C2) were injected on day 1 and the group receiving 4 shots (Group B3) was injected on days 1, 2, 3 and 4. All shots were administered via the route of subcutaneous injection.
  • Figure 16 shows that pre-treating the mice with CPA caused neutropenia, i.e., a reduced the neutrophil counts in the blood of treated mice ( compare days -3 and 0 with day 1 in all samples).
  • the neutropenia was found to be temporary and the level of neutrophils slowly returned to pre-CPA treatment levels after about 8 days in the control group (see results for Group A).
  • GCSF-sFc GCSF single chain Fc fusion protein of the present disclosure
  • a fusion protein was prepared having a structure of formula 1 discussed above: (B)-(Hinge)-(C H 2-C H 3) wherein:
  • the IFN ⁇ -sFc was produced using a DNA expression vector.
  • the DNA fragment of the IPN ⁇ -sFc was assembled using overlapping primers by the method of assembly polymerase chain reaction (PCR).
  • PCR assembly polymerase chain reaction
  • the assembled IFN ⁇ -sFc fragment was then ligated into PacI and EcoRV sites of pZD vector (pcDNA3.1Neo, Invitrogen, Carlsbad, CA, cat. no.V790-20 with dhfr gene) to obtain pZD/IFNb-sFc as shown in Figure 17 and then transformed into E. coli.
  • the expression vector construct contained the zeocin-resistance gene as a selection marker.
  • CHO dhfr- cells were trypsinized and resuspended at a concentration of 3 ⁇ 10 6 cells/mL in CP-T buffer (Cyto pluse Cat. CP-T).
  • 0.2 mL of cell suspension (6 ⁇ 10 5 cells) was transfected with 10 ⁇ g of plasmid pZD-IFN ⁇ -sFc by electroporation (PA4000 PulseAgile ® electroporator, Cyto Pulse Sciences). After 48 hrs of growth in non-selective medium, the transfectants were incubated in the selective complete medium containing IMDM, 10% fetal bovine serum, Zeocin (Invitrogen Cat.
  • the original Z-BsFc cells were cultivated in a 10-cm dish containing IMDM supplemented with 10% FBS, zeocin, and 0.1 ⁇ M MTX.
  • Cells were maintained in a 37°C humidified 95% air/5% CO 2 incubator (Model 3326, Forma Scientific).
  • the medium was changed from IMDM to JRH serum-free medium supplemented with 5% FBS, zeocin, and 0.1 ⁇ M MTX.
  • the cells were detached from 10-cm dish by trypsinization and then transferred to spinner flasks containing 50 mL JRH serum-free medium supplemented with the same percentage of FBS.
  • the concentration of IFN ⁇ -sFc fusion protein in serum samples were quantified by an in-house IPN ⁇ -sFc ELISA kit.
  • the serum dilution-fold was optimized and the plate layout for standards, controls, and specimens were determined before performing formal assays using the fusion protein.
  • Absorbance at wavelength 450 nm and 600 nm was acquired by SoftMax ® Pro 5 software.
  • High-yield clones were successfully obtained by selection, limiting dilution and stepwise MTX challenges to produce finally the fusion protein comprising the recombinant IFN beta linked to single chain Fc (i.e., IFN ⁇ -sFc).
  • the resulting fusion protein was purified for further in vitro or in vivo biological activity assays and pharmacokinetics studies.
  • Protein A based resin (MabSelect SuRe TM ) was used to purify IFN ⁇ -sFc. After purification, the corresponding recovery rate was analyzed by quantitative ELISA, and the respective purity by SDS-PAGE. The detailed purification process for IFN ⁇ -sFc is described below.
  • Blood samples were collected at 5 min, 0.5, 1, 4, 7, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after injection respectively and then centrifuged at 3,000 rpm for 20 minutes. The supernatants were stored at -70°C.
  • the interferon concentrations in serum samples were quantified by VeriKine TM Human IFN Beta ELISA Kit (PBL assay science, CN.: 41410) for IFN ⁇ .
  • the absorbances at wavelength 450 nm and 600 nm were acquired by SoftMax ® Pro 5 software.
  • the Cmax, Tmax, AUC values, and the elimination phase half-life (T 1/2 ) from the interferon concentrations in serum were calculated by PK Solutions 2.0 TM software.
  • the subcutaneous (S.C.) pharmacokinetic profiles of IFN ⁇ in rats after administration with a single dose are shown in Figure 18 and the mean pharmacokinetic features are reported in Table 15.
  • the half-life of Rebif ® and IFN ⁇ -sFc was 18.92-23.57 and 31.89-37.7 hrs, respectively.
  • the Cmax of Rebif ® and IFN ⁇ -sFc was 3.2 ⁇ 0.71 and 6.55 ⁇ 0.78 ng/mL, respectively.
  • the Tmax of Rebif ® and IFN ⁇ -sFc was 12 ⁇ 0 and 9.55 ⁇ 3.61 hrs, respectively.
  • the AUC of Rebif ® and IFN ⁇ -sFc was 115 ⁇ 18.38 and 273 ⁇ 2.83 ng-hr/mL, respectively.
  • the IFN ⁇ - sFc of this invention exhibited improvement in half-life extension as shown in Figure 18 and Table 15 when compared to that of Rebif ® (the native form of IFN ⁇ ).
  • IFN ⁇ is an anti-inflammatory cytokine and serves as one of the major drugs for multiple sclerosis (MS) treatment.
  • MS is the most common inflammatory disease of the central nervous system. The immune cells cross the blood brain barrier and attack myelin, leading to ineffective conduction of signals in nervous systems of MS patients. Injections of IFN ⁇ drug several times per week is necessary to control the relapse of MS.
  • the anti-inflammatory mechanism of IFN ⁇ on MS has been reported to involve a shift in cytokine balance from Th1 to Th2 in the T-cell response against elements of the myelin sheath.
  • Th1 and Th2 groups two other important pro-inflammatory cytokines, including osteopontin (OPN), have been found to play important roles in CNS inflammation in the pathogenesis of MS.
  • IFN ⁇ has been shown to inhibit the production of OPN in primary T cells derived from PBMC and the inhibition occurs at the CD4+ T-cell level.
  • the biological activity of IFN ⁇ -sFc was evaluated in an osteopontin inhibition assay and its activity was compared to natural IFN ⁇ -1a (Rebif ® ).
  • the osteopontin inhibition assay was carried out as follows: Human PBMCs were isolated from whole blood. For PBMC stimulation, 96-well flat-bottom tissue culture plate was pre-coated with 100 ⁇ l of anti-CD3 antibody at 1 ⁇ g/mL concentration per well and incubated overnight at 4°C. Each well was washed with 200 ⁇ l RPMI 1640 (with FBS), and seeded with 5 ⁇ 10 4 cells.
  • the single chain Fc fusion protein of the present disclosure significantly inhibited the production of OPN in cells treated with 1.5 ng/mL (73.4 ⁇ 0.8%) and 10 ng/mL (79.5 ⁇ 3.6%) of the test article.
  • Cells treated with the reference article (Rebif ® ) demonstrated a similar inhibition of OPN at 1.5 ng/mL (88.4 ⁇ 2.7%) and 10 ng/mL (81.3 ⁇ 13.3%).
  • Relative potency 1 1 1.09 1 Relative potency is the ratio of the specific activity of the test sample compared to the specific activity of Recombinant FIX (i.e., 200 IU/mg) TABLE 9 Pharmacokinetics Features of Interferons in Rats After Subcutaneous Administration Pegasys ® (Pegylated-IFN ⁇ ) IFN ⁇ -sFc PEG-Intron ® (Pegylated-IFN ⁇ ) Roferon-A ® (recombinant-IFN ⁇ ) Half-life (Hr) 23.2 50.2 20.8 0.73 Cmax (pM) 820.6 677.6 182.1 213.0 Tmax (H
  • the term "monomer” reflects a sFc fragment incapable of forming a disulfide-bonded dimer 3
  • the term “monomer” reflects a sFc fragment capable of forming a disulfide-bonded dimer TABLE 11 Binding Affinity Features of IFN ⁇ -sFc ( sFc fragment incapable of forming a disulfide-bonded dimer) and IFN ⁇ -Fc ( sFc fragment capable of forming a disulfide-bonded dimer) to IFNAR1 Ka (1/Ms) Kd (1/s) KD (nM) IFN ⁇ -sFc (Monomer) 1.4E+06 5.6E-03 4.0E-09 IFN ⁇ -Fc (Dimer) 3.3E+06 5.6E-02 1.8E-08 TABLE 12 Pharmacokinetics Features of GCSFs in Rats After Subcutaneous Administration GCSF-sFc Granocyte ® (Lenograstim) Neulasta ® (Peg

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

  1. Fusionsprotein, das in einer Säugetierzelle hergestellt ist, umfassend:
    a) ein bioaktives Molekül, das aus der Gruppe bestehend aus Erythropoietin, Faktor IX, IFNα, GCSF, und INFß ausgewählt ist; und
    b) ein einkettiges Fc-(sFc)-Fragment eines IgG-Moleküls mit einer Aminosäuresequenz, die aus der Gruppe bestehend aus SEQ ID NOs: 61, 62, 63, und 64 ausgewählt ist,
    c) eine Gelenkregion zwischen dem bioaktiven Molekül und dem sFc-Fragment, wobei die Gelenkregion mutiert ist und keine Disulfidbindungen mit einem anderen Fusionsprotein oder einem anderen Immunglobulinmolekül bildet, und wobei die Gelenkregion eine Aminosäuresequenz umfasst, die aus der Gruppe bestehend aus SEQ ID NOs: 23-60 ausgewählt ist.
  2. Fusionsprotein nach Anspruch 1, wobei die Gelenkregion eine Aminosäuresequenz der SEQ ID NO: 23 oder 27 umfasst.
  3. Fusionsprotein nach Anspruch 1, wobei das bioaktive Molekül eine Aminosäuresequenz aufweist, die aus der Gruppe bestehend aus SEQ ID NOs: 65, 67, 69, 71, und 73 ausgewählt ist.
  4. Fusionsprotein nach Anspruch 1, wobei die Aminosäuresequenz des Fusionsproteins aus der Gruppe bestehend aus SEQ ID NOs: 66, 68, 70, 72, und 74 ausgewählt ist.
  5. Pharmazeutische Zusammensetzung, umfassend das Fusionsprotein nach Anspruch 1 und einen pharmazeutisch akzeptablen Träger oder Hilfsstoff.
  6. Verfahren zur Herstellung eines Fusionsproteins in einer Säugetierzelle, umfassend:
    a) Bereitstellen eines bioaktiven Moleküls und eines sFc-Fragments, das eine Gelenkregion umfasst, wobei das bioaktive Molekül aus der Gruppe bestehend aus Erythropoietin, Faktor IX, IFNα, GCSF, und INFß ausgewählt ist;
    b) Mutieren der Gelenkregion des sFc-Fragments durch eine Aminosäuresubstitution und/oder Deletion, um eine mutierte Gelenkregion eines mutierten sFc-Fragments zu bilden, und
    c) Kombinieren des bioaktiven Moleküls und des mutierten sFc-Fragments durch die mutierte Gelenkregion,
    wobei die mutierte Gelenkregion eine Aminosäuresequenz umfasst, die aus der Gruppe bestehend aus SEQ ID NOs: 23-60 ausgewählt ist, und wobei die mutierte Gelenkregion keine Disulfidbindungen mit einem anderen Fusionsprotein oder einem anderen Immunglobulinmolekül bildet.
  7. Fusionsprotein, das in einer Säugetierzelle hergestellt ist, umfassend:
    a) ein einkettiges Fc-Fragment (sFc) eines IgG-Moleküls mit einer Aminosäuresequenz, die aus der Gruppe bestehend aus SEQ ID NOs: 61, 62, 63, und 64 ausgewählt ist;
    b) eine Gelenkregion, die eine Aminosäuresequenz umfasst, die aus der Gruppe bestehend aus SEQ ID NOs: 23-60 ausgewählt ist; und
    c) ein bioaktives Molekül mit einer Aminosäuresequenz, die aus der Gruppe bestehend aus SEQ ID NOs: 65, 67, 69, 71, und 73 ausgewählt ist.
  8. Fusionsprotein nach Anspruch 7, wobei die Aminosäuresequenz der Gelenkregion SEQ ID NO: 23 oder 27 ist.
EP16808386.3A 2015-06-12 2016-06-10 Immunglobulin-fusionsproteine und verwendungen davon Active EP3307304B1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562175186P 2015-06-12 2015-06-12
US15/002,396 US20160362473A1 (en) 2015-06-12 2016-01-20 Immunoglobulin fusion proteins and uses thereof
US15/177,605 US11820807B2 (en) 2015-06-12 2016-06-09 Immunoglobulin fusion proteins and uses thereof
PCT/US2016/036915 WO2016201244A1 (en) 2015-06-12 2016-06-10 Immunoglobulin fusion proteins and uses thereof

Publications (3)

Publication Number Publication Date
EP3307304A1 EP3307304A1 (de) 2018-04-18
EP3307304A4 EP3307304A4 (de) 2018-12-26
EP3307304B1 true EP3307304B1 (de) 2024-05-08

Family

ID=60763749

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16808386.3A Active EP3307304B1 (de) 2015-06-12 2016-06-10 Immunglobulin-fusionsproteine und verwendungen davon

Country Status (9)

Country Link
US (2) US20240228587A9 (de)
EP (1) EP3307304B1 (de)
JP (1) JP7136690B2 (de)
KR (1) KR20180032551A (de)
CN (1) CN107835693B (de)
AU (1) AU2016274890B2 (de)
BR (1) BR112017026713A2 (de)
CA (1) CA2989116A1 (de)
HK (1) HK1251456A1 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004042017A2 (en) * 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
KR100927261B1 (ko) 2001-01-17 2009-11-18 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인-면역글로불린 융합 단백질
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP4870569B2 (ja) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
EP2144930A1 (de) * 2007-04-18 2010-01-20 ZymoGenetics, Inc. Einzelketten-fc sowie herstellungsverfahren dafür und bearbeitungsverfahren dafür
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
WO2011063348A1 (en) * 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
NZ605400A (en) 2010-07-09 2015-05-29 Biogen Idec Hemophilia Inc Chimeric clotting factors
EP2603526A1 (de) 2010-08-13 2013-06-19 Medimmune Limited Monomere polypeptide mit abweichenden fc-regionen und verwendungsverfahren
KR101853405B1 (ko) * 2010-10-20 2018-05-02 주식회사 티움바이오 인자 ｉｘ 활성을 갖는 융합 단백질
EP3144320B9 (de) * 2011-04-13 2018-08-22 Bristol-Myers Squibb Company Fc-fusionsproteine mit neuartigen linkern oder anordnungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004042017A2 (en) * 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production

Also Published As

Publication number Publication date
AU2016274890B2 (en) 2022-02-10
BR112017026713A2 (pt) 2018-08-28
US20240182545A1 (en) 2024-06-06
CN107835693B (zh) 2021-11-02
CA2989116A1 (en) 2016-12-15
EP3307304A1 (de) 2018-04-18
US20240228587A9 (en) 2024-07-11
CN107835693A (zh) 2018-03-23
HK1251456A1 (zh) 2019-02-01
JP2018518533A (ja) 2018-07-12
AU2016274890A1 (en) 2018-01-18
EP3307304A4 (de) 2018-12-26
US20240132572A1 (en) 2024-04-25
JP7136690B2 (ja) 2022-09-13
AU2016274890A8 (en) 2018-01-25
KR20180032551A (ko) 2018-03-30

Similar Documents

Publication Publication Date Title
US11820807B2 (en) Immunoglobulin fusion proteins and uses thereof
US20160362473A1 (en) Immunoglobulin fusion proteins and uses thereof
RU2736339C1 (ru) Слитый белок человеческого фактора свертывания IХ (FIX), способ его получения и применения
CA2758445C (en) In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
CN1723219B (zh) 利用免疫球蛋白片段的蛋白质复合物及其制备方法
EP2408474B1 (de) Zusammensetzungen und verfahren zur verabreichung von igg-köderrezeptor-fusionsproteinen in die blut-hirn-schranke
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
CN108136276B (zh) 通过使用免疫球蛋白片段的特异性位点进行连接的蛋白质复合物
US10023624B2 (en) Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein
EP2612676A1 (de) Verwendung eines g-csf-dimers in der behandlung von neutropenie
KR20180071241A (ko) FcRn 결합력이 유지되는 면역글로불린 Fc 결합체
US20230312682A1 (en) SIRPalpha-FC FUSION PROTEIN
EP3307304B1 (de) Immunglobulin-fusionsproteine und verwendungen davon
KR20220041058A (ko) pH-감응성 Fc 변이체
KR102478588B1 (ko) 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법
WO2015161832A1 (zh) 长效重组人干扰素α2b-Fc融合蛋白

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UBI PHARMA INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181128

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/565 20060101ALI20181123BHEP

Ipc: C07K 19/00 20060101ALI20181123BHEP

Ipc: C07K 16/40 20060101ALI20181123BHEP

Ipc: C07K 14/535 20060101ALI20181123BHEP

Ipc: A61K 39/00 20060101AFI20181123BHEP

Ipc: A61K 39/395 20060101ALI20181123BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191018

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20231219

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240415

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016087445

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240617

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240617

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240528

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240625

Year of fee payment: 9

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240626

Year of fee payment: 9

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240508

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240909

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1684459

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240508